<unk> , sold under the brand name Belsomra, is an orexin antagonist medication which is used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults.<unk>  helps with falling asleep faster, sleeping longer, being awake less in the middle of the night, and having better quality of sleep. The medication is taken by mouth. Side effects of<unk>  include somnolence, daytime sleepiness and sedation, headache, dizziness, abnormal dreams, dry mouth, and impaired next-day driving ability. Rarely, sleep paralysis, sleep-related hallucinations, complex sleep behaviors like sleepwalking, and suicidal ideation may occur. Tolerance, dependence, withdrawal, and rebound effects do not appear to occur with the medication.<unk>  is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin OX1 and OX2 receptors. The medication has an intermediate elimination half-life of 12hours and a time to peak of about 2 to 3hours.<unk>  is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action. Clinical development of<unk>  began in 2006 and it was introduced for medical use in 2014. The medication is a schedule IV controlled substance in the United States and may have a modest potential for misuse. Conversely,<unk>  is not a controlled substance in Australia.<unk>  is not available in generic formulations.
Suvorexant
Icatibant
Veristrat
Seltorexant
Daridorexant
Rimegepant
Atogepant
Ubrogepant